1,9-dimethylmethylene blue has been researched along with Serotonin Syndrome in 1 studies
*Serotonin Syndrome: An adverse drug interaction characterized by altered mental status, autonomic dysfunction, and neuromuscular abnormalities. It is most frequently caused by use of both serotonin reuptake inhibitors and monoamine oxidase inhibitors, leading to excess serotonin availability in the CNS at the serotonin 1A receptor. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Delport, A; Harvey, BH; Petzer, A; Petzer, JP | 1 |
1 other study(ies) available for 1,9-dimethylmethylene blue and Serotonin Syndrome
| Article | Year |
|---|---|
The monoamine oxidase inhibition properties of selected structural analogues of methylene blue.
Topics: Benzoxazines; Binding Sites; Dose-Response Relationship, Drug; Humans; Methylene Blue; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neutral Red; Oxazines; Protein Binding; Recombinant Proteins; Risk Assessment; Serotonin Syndrome; Structure-Activity Relationship | 2017 |